MacdougallI.C.Merits of percentage hypochromic red cells as a marker of functional iron deficiency. Nephrol Dial Transplant1998; 13: 847–9.
2.
BoddyK., LawsonD.H., LintonA.L., WillG.Iron metabolism in patients with chronic renal failure. Clin Sci1970; 39: 115–21.
3.
BeamishM.R., DaviesA.G., EakinsJ.D.The measurement of reticuloendothelial iron release using iron-dextran. Br J Haemat1971; 21: 617–22.
4.
BaldusM., WalterH., ThiesK.Transferrin receptor assay and zinc protoporphyrin as markers of iron-deficient erythropoiesis in end-stage renal disease patients. Clin Nephrol1998; 49: 186–92.
5.
FishbaneS., GalganoC., LangleyR.C.Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients. Kidney Int1997; 52: 217–22.
6.
HorlW.H.Measurement of hypochromic red blood cells is not the first line procedure to identify the patients with iron deficiency. Nephrol Dial Transplant1998; 13: 850–1.
7.
HendersonP.A., HillmanR.S.Characteristics of iron dextran utilization in man. Blood1969; 34: 357–75.
8.
GrimesA.J., HuttM.S.R.Metabolism of 59Fe-Dextran complex in human subjects. BMJ1957; 2: 1074–7.
9.
DanielsonB.G., SalmonsonT., DerendorfH.Pharmacokinetics of iron (III)-hydroxidesucrose complex after a single intravenous dose in healthy volunteers. Arzneimittel-Forschung.1996; 46: 615–21.
BaranyP., Divino FilhoJ.C., BergstromJ.High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am J Kidney Dis1997; 29: 565–8.
12.
BedaniP.L., CecchettiE., GilliP.Effectiveness of subcutaneous low-dose erythropoietin in patients with chronic renal failure despite functional iron deficiency. Nephron1995; 71: 459–60.
13.
WillG., GrodenB.M.The treatment of iron deficiency anaemia by iron-dextran infusion: a radio-isotope study. Br J Haemat1968; 14: 61–71.
14.
AlbitarS., MeuldersQ., HammoudH.Subcutaneous versus intravenous administration of erythropoietin improves efficiency for the treatment of anaemia in hemodialysis patients. Nephrol Dial Transplant1995; 6: 40–3.
15.
KaufmanJ.S., RedaD.J., FyeC.L.Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. N Engl J Med1998; 339: 578–83.
16.
IfuduO., DawoodM., FriedmanE.A.Relative contributions of body iron status and uremia severity to anemia in patients with advanced chronic renal failure. Nephron1997; 77: 315–18.
17.
SilverbergD.S., IainaA., PeerG.Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis1996; 27: 234–38.
18.
RadkeH.W., RegeA.B., LaMarcheM.B.Identification of spermine as an inhibitor of erythropoiesis in patients with chronic renal failure. J Clin Invest1980; 67: 1623–29.
19.
WallnerS.F., VautrinR.M.Evidence that inhibition of erythropoiesis is important in the anemia of chronic renal failure. J Lab Clin Med1981; 97: 170–8.
20.
SantiagoG.C., RaoT.K., LairdN.M.Effect of dialysis therapy on the hematopoietic system: The National Cooperative Dialysis Study. Kidney Int1983; 23(suppl.): S95–100.
21.
IfuduO., FeldmanJ., FriedmanE.A.The intensity of hemodialysis and the response to erythropoietin in patients receiving hemodialysis. N Engl J Med1996; 334: 420–5.
